An observational study in IgG4-Related Diseases, sponsored by Peking Union Medical College Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Peking Union Medical College Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital — 7 open to participants now, 7 under way, 1 of them phase 3. Immunoglobulin G4-Related Disease · Peking Union Medical College Hospital.
Among the 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital, this one is the only one that started in 2027, is one of 4 observational ones, and was the 15th registered.
73 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 39 are open to participants now.
Browse Immunoglobulin G4-Related Disease studies →7 of the 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital are open now, in 1 country. Recruiting first, the newest first:
Peking Union Medical College Hospital · Sites in China
Ages 18–75
Peking Union Medical College Hospital · Sites in China
Ages 18–75
Peking Union Medical College Hospital · Sites in China
Ages 18–75
Peking Union Medical College Hospital · Sites in China
Peking Union Medical College Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 27 Immunoglobulin G4-Related Disease studies recruiting now, 11 (41%) set no upper age limit and 13 (48%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 2 · Phase 4 1
First in 2012; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 124 across 19 observational studies indexed under Immunoglobulin G4-Related Disease.
Median enrollment 74 across the 11 interventional studies, 780 across the 4 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Peking Union Medical College Hospital is the lead sponsor of 1,158 studies on the registry; 477 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
1 of the studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03023371Peking Union Medical College HospitalNational Registry of IgG4-RD in China | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to observe the efficacy and safety of inebilizumab in the treatment of IgG4-related disease. The main question it aims to answer the optimal steroid-sparing regimen for patients with IgG4-RD in clinical practice.
This study will enroll all patients with IgG4-RD treated with inebilizumab. Enrolled patients will receive different treatment regimens according to disease severity and whether they are taking other immunosuppressive agents.
All enrolled patients will be categorized into four subtypes based on disease severity and concomitant use of other immunosuppressive agents:
Group1 Treatment-naive active disease treated with inebilizumab monotherapy group: treatment-naive patients or patients with post-discontinuation relapse, in whom the investigator assesses that the disease is suitable for inebilizumab monotherapy; Group2 Treatment-naive active disease treated with short-course corticosteroids plus inebilizumab group: treatment-naive patients or patients with post-discontinuation relapse, in whom the investigator assesses that short-course corticosteroids are required in combination; Group3 Stable disease continued-treatment group: patients with stable disease control on long-term corticosteroids or corticosteroids plus conventional immunosuppressants, who are at high risk of relapse after discontinuation and are willing to switch to a steroid-free inebilizumab treatment regimen; Group4 Relapsed/refractory patient group: patients who experience relapse while receiving corticosteroids or corticosteroids combined with immunosuppressants.
All IgG4-related disease patients treated with inebilizumab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with IgG4-RD receiving inebilizumab in the real-world setting
Relapse rate
Flare of IgG4-RD is defined as the reappearance of previous symptoms or signs of IgG4-RD or the appearance of new symptoms or signs attributed to IgG4-RD, based on clinical assessment, laboratory tests, and/or imaging, and reflected by an increase in the IgG4-RD Responder Index
Time frame: One year after inebilizumab treatment
Proportion of subjects achieving flare-free and treatment-free complete remission
Flare-free and treatment-free complete remission was defined as the absence of any disease flare, no glucocorticoid for flare, and the absence of disease activity
Time frame: Three Months, six months and twelve months after inebilizumab treatment
Proportion of subjects achieving flare-free and glucocorticoid-free complete remission
Flare-free and glucocorticoid-free complete remission was defined as the absence of any disease flare, no glucocorticoid for flare, and the absence of disease activity
Time frame: Three Months, six months and twelve months after inebilizumab treatment
Remission rate after inebilizumab treatment
The investigator determined that there was no evidence of disease activity at the visit
Time frame: Six months and twelve months after inebilizumab treatment
IgG4-RD Responder Index (IgG4-RD RI) after inebilizumab treatment
Measured by IgG4-RD Responder Index
Time frame: Three Months, six months and twelve months after inebilizumab treatment
IgG4-RD Damage Index (IgG4-RD DI) after inebilizumab treatment
Measured by IgG4-RD Damage Index
Time frame: Three Months, six months and twelve months after inebilizumab treatment
Changes in serum IgG4 levels from baseline after inebilizumab treatment
Laboratory markers
Time frame: Three Months, six months and twelve months after inebilizumab treatment
Changes in serum B-cell levels from baseline after inebilizumab treatment
Laboratory markers
Time frame: Three Months, six months and twelve months after inebilizumab treatment
Total amount of glucocorticoids during inebilizumab administration
Total amount of glucocorticoids calculated as the cumulative glucocorticoid dose (in milligrams) taken for the purpose of IgG4-RD disease control. This measure accounted for all glucocorticoids treatments administered to participants to manage disease activity throughout the study period.
Time frame: One year after inebilizumab treatment
Improvement in patients' quality of life during inebilizumab administration
Quality of life measured by the EQ-5D-5L questionnaire
Time frame: One year after inebilizumab treatment
No study locations are listed for this record.
Plan to share: No — IPD will not be shared with other researchers. Data may be made available to regulatory authorities, trial monitors, auditors, and ethics committees as required for trial oversight, monitoring, audit, and verification.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Immunoglobulin G4-Related Disease →
Peking Union Medical College Hospital →